Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F

Virology

Volumn 365, Issue 1, 2007, Pages 92-100

  Yang, Yiliang ^a   Guo, Fei ^a   Cen, Shan ^a,b,c   Kleiman, Lawrence ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

APOBEC3F; APOBEC3G; Inhibition of HIV 1 reverse transcription

Indexed keywords

CYTIDINE; GENOMIC RNA; TRANSFER RNA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DNA TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; VIRION;

CYTOSINE DEAMINASE; HIV-1; HUMANS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34250186071     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.03.022     Document Type: Article

References (44)

1. Alce T.M., and Popik W. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 279 33 (2004) 34083-34086
2. Arts E.J., Li X., Gu Z., Kleiman L., Parniak M.A., and Wainberg M.A. Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J. Biol. Chem. 269 20 (1994) 14672-14680
3. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., and Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14 15 (2004) 1392-1396
4. Bishop K.N., Holmes R.K., and Malim M.H. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80 (2006) 8450-8458
5. Bogerd H.P., Wiegand H.L., Doehle B.P., Lueders K.K., and Cullen B.R. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res. 34 1 (2006) 89-95
6. Butler S.L., Hansen M.S., and Bushman F.D. A quantitative assay for HIV DNA integration in vivo. Nat. Med. 7 5 (2001) 631-634
7. Cen S., Khorchid A., Gabor J., Rong L., Wainberg M.A., and Kleiman L. The role of Pr55gag and NCp7 in tRNALys3 genomic placement and the initiation step of reverse transcription in HIV-1. J. Virol. 74 (2000) 10796-10800
8. Cen S., Guo F., Niu M., Saadatmand J., Deflassieux J., and Kleiman L. The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 279 32 (2004) 33177-33184
9. + T cells. Nature 435 7038 (2005) 108-114
10. Cullen B.R. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J. Virol. 80 3 (2006) 1067-1076
11. Dang Y., Wang X., Esselman J., and Zheng Y.-H. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80 (2006) 10522-10533
12. Dettenhofer M., Cen S., Carlson B.A., Kleiman L., and Yu X.F. Association of HIV-1 Vif with RNA and its role in reverse transcription. J. Virol. 74 (2000) 8938-8945
13. Doehle B.P., Schafer A., and Cullen B.R. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339 2 (2005) 281-288
14. Goncalves J., Korin Y., Zack J., and Gabuzda D. Role of Vif in human immunodeficiency virus type 1 reverse transcription. J. Virol. 70 12 (1996) 8701-8709
15. Guo F., Cen S., Niu M., Saadatmand J., and Kleiman L. The inhibition of tRNALys3-primed reverse transcription by human APOBEC3G during HIV-1 replication. J. Virol. 80 (2006) 11710-11722
16. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., and Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 113 6 (2003) 803-809
17. Holmes R.K., Koning F.A., Bishop K.N., and Malim M.H. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation: comparisons with APOBEC3G. J. Biol. Chem. 282 (2007) 2587-2595
18. Huang Y., Shalom A., Li Z., Wang J., Mak J., Wainberg M.A., and Kleiman L. Effects of modifying the tRNALys3 anticodon on the initiation of human immunodeficiency virus type 1 reverse transcription. J. Virol. 70 (1996) 4700-4706
19. Lys incorporation into HIV-1. J. Virol. 71 (1997) 4378-4384
20. Huang Y., Wang J., Shalom A., Li Z., Khorchid A., Wainberg M.A., and Kleiman L. Primer tRNALys3 on the viral genome exists in unextended and two base-extended forms within mature human immunodeficiency virus type 1. J. Virol. 71 (1997) 726-728
21. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., and Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79 3 (2002) 285-296
22. Jiang M., Mak J., Ladha A., Cohen E., Klein M., Rovinski B., and Kleiman L. Identification of tRNAs incorporated into wild-type and mutant human immunodeficiency virus type 1. J. Virol. 67 6 (1993) 3246-3253
23. Kaiser S.M., and Emerman M. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J. Virol. 80 2 (2006) 875-882
24. Khan M.A., Kao S., Miyagi E., Takeuchi H., Goila-Gaur R., Opi S., Gipson C.L., Parslow T.G., Ly H., and Strebel K. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 79 9 (2005) 5870-5874
25. Langlois M.A., Beale R.C., Conticello S.G., and Neuberger M.S. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res. 33 6 (2005) 1913-1923
26. Levin J.G., Guo J., Rouzina I., and Musier-Forsyth K. Nucleic acid chaperone activity of HIV-1 nucleocapsid protein: critical role in reverse transcription and molecular mechanism. Prog. Nucleic Acid Res. Mol. Biol. 80 (2005) 217-286
27. Liddament M.T., Brown W.L., Schumacher A.J., and Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14 15 (2004) 1385-1391
28. Luo K., Liu B., Xiao Z., Yu Y., Yu X., Gorelick R., and Yu X.F. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 78 21 (2004) 11841-11852
29. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., and Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114 1 (2003) 21-31
30. Newman E.N., Holmes R.K., Craig H.M., Klein K.C., Lingappa J.R., Malim M.H., and Sheehy A.M. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15 2 (2005) 166-170
31. Rose K.M., Marin M., Kozak S.L., and Kabat D. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. AIDS Res. Hum. Retroviruses 21 7 (2005) 611-619
32. Rosler C., Kock J., Kann M., Malim M.H., Blum H.E., Baumert T.F., and von Weizsacker F. APOBEC-mediated interference with hepadnavirus production. Hepatology 42 2 (2005) 301-309
33. Schafer A., Bogerd H.P., and Cullen B.R. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328 2 (2004) 163-168
34. Selig L., Benichou S., Rogel M.E., Wu L.I., Vodicka M.A., Sire J., Benarous R., and Emerman M. Uracil DNA glycosylase specifically interacts with Vpr of both human immunodeficiency virus type 1 and simian immunodeficiency virus of sooty mangabeys, but binding does not correlate with cell cycle arrest. J. Virol. 71 6 (1997) 4842-4846
35. Turelli P., Mangeat B., Jost S., Vianin S., and Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 303 5665 (2004) 1829
36. Waters L.C., and Mullin B.C. Transfer RNA in RNA tumor viruses. Prog. Nucleic Acid Res. Mol. Biol. 20 (1977) 131-160
37. Wedekind J.E., Dance G.S., Sowden M.P., and Smith H.C. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet. 19 4 (2003) 207-216
38. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., and Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother 46 6 (2002) 1896-1905
39. Wiegand H.L., Doehle B.P., Bogerd H.P., and Cullen B.R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23 12 (2004) 2451-2458
40. Willetts K.E., Rey F., Agostini I., Navarro J.M., Baudat Y., Vigne R., and Sire J. DNA repair enzyme uracil DNA glycosylase is specifically incorporated into human immunodeficiency virus type 1 viral particles through a Vpr-independent mechanism. J. Virol. 73 2 (1999) 1682-1688
41. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., and Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302 5647 (2003) 1056-1060
42. Yu Q., Konig R., Pillai S., Chiles K., Kearney M., Palmer S., Richman D., Coffin J.M., and Landau N.R. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11 5 (2004) 435-442
43. Zennou V., Perez-Caballero D., Gottlinger H., and Bieniasz P.D. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 78 21 (2004) 12058-12061
44. Zheng Y.H., Irwin D., Kurosu T., Tokunaga K., Sata T., and Peterlin B.M. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78 11 (2004) 6073-6076